Trial Profile
Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.
- 01 Mar 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 01 Mar 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.